Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Renmark 2 employees. Renmark Financial Communications Inc is located in Toronto, ON, Canada and is part of the Consulting Services Industry. Renmark Financial Communications Inc has 2 total employees across all of its locations and generates $459,446 in sales (USD).
WOW! Look at the numbers. Way worse than ever. And yes These people must be really, really stupid. They should not be running a lemonade stand, let alone run am company.
What a disaster this POS has become. Sales dropping like a rock. Blew millions on this Reds, that does'nt sell. No one accountable. Blew all the cash they had on shares. Bad outlook. No wonder shares do not trade. Are these people stupid?
News Medicure Announces SMILE™-HF Study Demonstrates Use of ReDS™ Results in 58% Reduction in Hospital Readmission Rate
NEWS PROVIDED BY
Medicure Inc.
Oct 15, 2019, 08:30 ET
WINNIPEG, Oct. 15, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the primary results of the late-breaking SMILETM-Heart Failure (SMILE-HF) Clinical Trial which was presented at the recent Heart Failure Society of America ("HFSA") conference in Philadelphia, PA by Dr. William T. Abraham, the SMILE-HF national principal investigator.
The SMILE-HF trial demonstrated that when used as intended, Remote Dielectric Sensing (ReDS™) treatment guided heart failure management prevented 58% of heart failure readmission(s). Data was collected from 268 patients by 43 centers across the United States, constituting the largest randomized control trial to date on the impact of ReDS™ on managing heart failure. Patients were recruited for the study during hospitalization and followed for up to 9 months at home. Daily measurements were taken using ReDS™ with the goal of keeping lung fluid content within the normal range of 20-35%. Data aggregated in the cloud was sent to physicians to monitor and adjust medication with the goal to keep each patient's fluid status balanced and avoid hospital readmission.
As previously announced on January 28, 2019, Medicure entered into an agreement with Sensible Medical Innovations Inc. ("Sensible") to become the exclusive marketing partner for ReDSTM in the United States and Medicure continues to hold a 7.71% equity stake on a fully diluted basis in Sensible.
"ReDS™ is an easy-to-use, non-invasive, point-of-care tool that we believe should be in the hands of every healthcare team who monitors and manages patients living with heart failure. We are extremely excited about these new results and believe this adds further evidence and value to support the use of ReDS™ as a primary tool to keep patients living with heart failure out of the hospital" said Dr. Albert Friesen, Chief Executive Officer for Medicure.
About SMILE™-HF
The SMILE™-HF study was a U.S. based prospective, randomized controlled multicenter trial conducted to investigate Remote Dielectric Sensing (ReDS™) guided treatment versus standard of care (SOC) following acute decompensated heart failure (ADHF) hospitalization. The primary endpoint of this study was to determine the rate of recurrent events of heart failure readmissions during the follow-up period.
About ReDS™ System
The ReDS™ is an accurate measurement tool to evaluate pulmonary congestion providing additional information to assist a physician in their assessment of a patient's condition. Assessment with the aid of ReDS™ technology has helped physicians at facilities across the country to better manage their patients' heart failure, with the goal of avoiding readmissions. For more information please visit www.medicure.com/reds.
Indications and Contraindications
ReDS is intended for use by qualified health care practitioners and by patients, under the direction of a physician, in hospitals, hospital-type facilities and home environment, for the non-invasive monitoring and management of patients with fluid management problems in a variety of medically accepted clinical applications.
ReDS is indicated for patients:
With fluid management problems
Taking diuretic medication
Living with Heart Failure
Recovering from Coronary Artery Disease related event
The ReDS system is not appropriate for patients with rib fractures, with or without flail chest.
About Medicure
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin) tablets and the ReDS™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com.
About Sensible Medical
Sensible Medical is a market leader in medical radar monitoring and imaging technology. ReDS™ was adapted for medical use from military 'see-through-wall' technology. The technology is well-positioned to be a difference maker in a wide range of applications and to become the next-generation lung fluid monitoring modality. www.sensible-medical.com.
To be added to Medicure's e-mail list, please visit:
http://medicure.mediaroom.com/alerts
I can see why everyone left MCU. They have done squat to get this moving in the last couple of years. They do have a clean balance sheet. But they put another academic on the board. Should never have let the son in law go. This should be doing 100 M a year by now. The only one buying this stock is MCU. No one else. Get someone in charge with some vision and list on an American exchange or this will hang in limbo forever.
Now we know why it has been headed down for the last month. This is getting ugly. If this old man Friesen is back in charge, this is done. He ran it into the ground once and he will do it again.
This has got to be a weak dollar downtrend.
It is creeping up nicely!
Where did everyone go? I have hung onto this pos after a lot of bad MCU years. Thought they were BK after the phase III blowup. Kicked the old guy out. Resurrected this dead company and finally made it profitable. Now it's running up and it looks like it could headed for 20-30 bucks.
MCUJF - Sales are ramping up. Up $2M for the quarter from the previous year. Over 100% growth. Expecting slaes to continue to increase at an accelerated pace.
MCUJF - Expanded product line would be great. But I am focused on the pace of growth of AGGASTAT. Could begin growing in the millions of dollars per month soon, if it hasn't already.
Long overdue...
No one said the Canadians were ever in a hurry to get'er done...But they finally are doing it...
Great post. Can't wait for earnings and guidance. Expecting some news on their investment on apricor. They just raised money so I think they put it to use to expand product line
MCUJF - Hospital Cath Labs are switching from more expensive options such as REOPRO and INTEGRILIN to AGGRASTAT. Most of these conversions are happening without the need for an expensive sales/commercial team.
The cost savings to the institutions are significant. Anywhere from 50% to 70% cost savings opportunity. When you are factoring in a $600 to $900 saving per patient undergoing PCI, there are hospitals and health systems that could save 10's of thousands to 100's of thousands of dollars on the hospital level...Millions of dollars on the large system level.
High dose AGGRASTAT may offer additional safety benefits over REOPRO and INTEGRILIN in patients undergoing PCI, as well as equivalent efficacy data...No large trials to directly compare these agents, but enough data in the literature to formulate a solid hypothesis...
MERCK screwed up years ago. They didn't listen to the key clinical trialists....
Which means...Great for anyone invested in Medicure at this point...
Also, with MDCO's anti-platelet option coming out at a higher price point, you may see an up-tic in GP IIb/IIIa inhibition utilization.
i would think there is something behind this run.
run forest run....MPH tsx.v up .40 or 15% so far today.....
Sales are increasing.
buying here today.....Medicure (symbol MPH) on the TSX.v is up 20% with strong volume in the last week....something is coming....
Looking strong today on good volume. 300K block bought earlier
Up on decent volume today. POZN just bought out TBUFF. Maybe this sparks these stocks
Yeah but I think this company will get more attention as their numbers continue to grow. They are diversifying their product line. Reminds me of a baby bioyf
MCUJF - Price moves quickly on low volume.
This company looks very interesting. Rapidly expanding product and they are diversifying. Seems very undervalued
Still here...
MCUJF
Look like this one will run off the next quarter filing.
..And another article..
Medicure (V.MPH) snags industry expert advisor and investors smell acquisition, up 26%
Good luck to all,
Sunpillar
Article on Medicure today..
Medicure Comments on Recent Trading Activity
Sunpillar
MCUJF - With today's news, this gets to $3 no problem.
Medicure mentioned as big day's gainer..
TSXV 10 Biggest Percentage Gainers Mid-Afternoon: Medicure, Omni-Lite, Immunovaccine
Hi STE,
Nice price movement today, quite a jump for sure!
Obviously the market liked today's news release.. However I am unfamiliar with Knight Therapeutics.
Any idea what this agreement really means for Medicure? (or what Medicure/Knight are really trying to achieve here?)
Good luck
MCUJF - Should get above $2, and get close to $3. Maybe even $4 before Aggrastat goes generic. They have some buying agreements with a large system or two. And with the data coming out of MDCO and angiomax losing to heparin, I see the class of drugs that Aggrastat is in making a rebound of sorts.
Hi STE,
Good to see you are still here! What are your long-term thoughts on this stock (sp and overall for company), now that they seem to be turning the corner?
I only wish I had not sold the majority of my shares at 75 cents! In any case I still have some and will hold onto them.. Considering I held them all when it went down to 0.5 cents (pre reverse-split) it should be much easier now LOL!
Good luck,
Sunpillar
MCUJF - $2 per share coming!
MCUJF - Should move higher. Next quarter the revenues should grow exponentially.
The earnings statement was a home run. That was a true profit off of aggrastat sales, not some one-time event.
correction--adfriesen@medicure.com and dreimer@medicure.com are no longer valid.
adfriessen@medicure.com and dawson reimer's email are no longer valid. Try a test email--either they have revised their emails or something else is going on. Also, Friessen's Genesys Ventures website is no longer around.
$12,000 in cash would last about a week in a small bio co. Noticed that the administrative costs were unreasonably high for a company this size; around 90% of revenue.
With Friessen's $500 monthly allotment for a car; hope this isn't another case of a founder bleeding a publicly-traded company of cash.
Their contact information should be somewhere on the board. A number of folks have posted it.
Does anyone have any information regarding an updated email address to either CEO Friessen or Dawson Reimer. Their former email address has been deleted.
Need to contact in regards to their limited cash levels and Medicure's ability to operate as a company going forward.
Thank you.
$12,000 in available cash as per the last 10Q. Potential for crash & burn is very high. Burned through the $200k grant and now running on fumes.
Correvio earned $30million+ per year for global sales of aggrastat...not a serious contender. And they got bought out by a company with a market cap around $70 million.
Hope the annual shareholder meeting (11/26) goes well, if any shareholders show up. Have to vote on their accountants compensation. By the way, bankrupt Savient Pharmaceuticals shares a similar market valuation with Medicure.
Bring on another reverse split.
MCUJF - Global rights of AGGRASTAT sold
Cardiome to Acquire Correvio LLC
Vancouver, Canada and GENEVA, November 18, 2013 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has completed the acquisition of Correvio LLC (“Correvio”), a privately held pharmaceutical company headquartered in Geneva, Switzerland. Key benefits of the transaction include the following:
Accelerates Cardiome’s launch of BRINAVESS™ (vernakalant IV) and its transformation into a global commercial organization positioned for future growth
Correvio is an EBITDA positive, European, specialty pharmaceutical company selling Aggrastat® (tirofiban HCL) to cardiologists in over 60 countries worldwide with annual revenues of US$30+ million
Brings together two highly complementary, in-hospital, intravenous, cardiology products sold through a direct sales force in Europe and via specialty distributors elsewhere
Reduces BRINAVESS build out costs and shortens the time to profitability by providing an established operational and financial infrastructure with significant operating cost synergies
Transaction expected to be accretive immediately
“The acquisition of Correvio markedly accelerates Cardiome’s recent transformation from a research and development-based company to an integrated, commercial, specialty pharmaceutical company. The Correvio acquisition fulfills many of our immediate strategic needs by providing an operational European platform, global distribution, complementary products and the financial flexibility required to accelerate the launch of BRINAVESS,” stated William Hunter, M.D., Cardiome’s president and CEO. “The cash contribution from synergistic sales of AGGRASTAT will lessen our reliance on external financing by providing low cost, ongoing funding while also shortening our road to profitability.”
“We have worked hard over the years to build a scalable infrastructure to successfully promote and support AGGRASTAT sales worldwide,” stated Bert Van Den Bergh, chairman of Correvio. “It’s exciting to see a growing product like BRINAVESS able to leverage off of our existing hospital-based, cardiology platform and capitalize on significant operational efficiencies.”
Under the terms of the agreement, Cardiome has acquired 100% of Correvio through the purchase of a combination of assets and shares of its subsidiaries in exchange for 19.9% of Cardiome’s outstanding shares (proforma ownership of approximately 16.6%) and a deferred cash consideration of US$12 M. The deferred cash consideration will be repaid monthly at an amount equal to 10% of cash receipts from product sales and any applicable interest accrued at 10% compounded annually. The adjusted deferred cash consideration must be repaid in full by December 1, 2019.
Conference Call
Cardiome will hold a teleconference and webcast to discuss the acquisition of Correvio at 5:00pm EST (2:00pm Pacific) on Monday, November 18th, 2013. To access the conference call, please dial (416) 764-8688 or (888) 390-0546 and use Conference ID: 08404139. The webcast can be accessed through Cardiome’s website at www.cardiome.com. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through December 16, 2013. Please dial 416-764-8677 or 888-390-0541 and enter code 404139 to access the replay.
About Aggrastat®
AGGRASTAT (tirofiban HCl) is a reversible GP IIb/IIIa inhibitor indicated for use in Acute Coronary Syndrome patients. The GP IIIb/IIa receptor is found on the platelet surface and is involved in platelet aggregation. AGGRASTAT prevents fibrinogen from binding to the GP IIb\IIIa receptor, thus blocking platelet aggregation. On October 9, 2013 the German regulatory agency BfArM, acting as the Reference Member State in the European Mutual Recognition Procedure (MRP), gave an approval on the indication statement for AGGRASTAT to include the reduction of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for primary PCI. Cardiome will support expansion of the AGGRASTAT label in other markets to also include use in STEMI patients.
About Cardiome Pharma Corp
Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit www.cardiome.com.
About Correvio
Correvio specializes in critical care with a deep understanding of interventional cardiology. Our business approach is to partner with healthcare professionals to help find the best therapeutic solution for their patients. In this context, we measure our success with Aggrastat® according to the number of Major Adverse Cardiac Events (MACE) prevented. Our Medical Information Centre (MIC) is available 24/7/365 to provide medical information support. For additional information about Correvio please visit www.correvio.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Forward- looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2013 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada, Europe, and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; and any other factors described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
For Further Information:
Cardiome Investor Relations
(604) 676-6993 or Toll Free: 1-800-330-9928
Email: ir@cardiome.com
Investor Contact:
Westwicke Partners, LLC
Robert H. Uhl
Managing Director
(858) 356-5932
robert.uhl@westwicke.com
Check the recent SEC quarterly filings for medicure...revenue increased substantially over the previous; new customers (ie hospitals) jumping on board. Had the first material event in years...and the bid values the company in the $2million range; go figure.
MCUJF - FDA label change for he better!
Whats up here? Besides the price?
TD trial has fallen off the map..."the recruitment status of this study is unknown because the information has not been verified recently."
Friesen claims to have zero failures with Genesys Ventures...wonder what he thinks medicure is?
More interest in stock options, changing accountants, new board members than actually doing something constructive. Interim TD analysis was expected late 2012; nothing but silence from managment. Will never ever invest in another canadian stock. Inmates in the US penal system can get more done than these canadian clowns.
MCUJF - The only thing that will save this company is a RM with the international AGG business. That too will be short lived since the management of that business are driving the global business into the ground also.
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1313
|
Created
|
10/18/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |